-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
SARS -X- _ O
outbreak -X- _ O
of -X- _ O
2002â€“2003 -X- _ O
presented -X- _ O
clinicians -X- _ O
with -X- _ O
a -X- _ O
new -X- _ O
, -X- _ O
life- -X- _ O
threatening -X- _ O
disease -X- _ O
for -X- _ O
which -X- _ O
they -X- _ O
had -X- _ O
no -X- _ O
experience -X- _ O
in -X- _ O
treating -X- _ O
and -X- _ O
no -X- _ O
research -X- _ O
on -X- _ O
the -X- _ O
effectiveness -X- _ O
of -X- _ O
treatment -X- _ O
options. -X- _ O
The -X- _ O
World -X- _ O
Health -X- _ O
Organization -X- _ O
( -X- _ O
WHO -X- _ O
) -X- _ O
expert -X- _ O
panel -X- _ O
on -X- _ O
SARS -X- _ O
treatment -X- _ O
requested -X- _ O
a -X- _ O
systematic -X- _ O
review -X- _ O
and -X- _ O
comprehensive -X- _ O
summary -X- _ O
of -X- _ O
treatments -X- _ O
used -X- _ O
for -X- _ O
SARS-infected -X- _ B-Patient
patients -X- _ I-Patient
in -X- _ O
order -X- _ O
to -X- _ O
guide -X- _ O
future -X- _ O
treatment -X- _ O
and -X- _ O
identify -X- _ O
priorities -X- _ O
for -X- _ O
research. -X- _ O
METHODS -X- _ O
AND -X- _ O
FINDINGS -X- _ O
: -X- _ O
In -X- _ O
response -X- _ O
to -X- _ O
the -X- _ O
WHO -X- _ O
request -X- _ O
we -X- _ O
conducted -X- _ O
a -X- _ O
systematic -X- _ O
review -X- _ O
of -X- _ O
the -X- _ O
published -X- _ O
literature -X- _ O
on -X- _ O
ribavirin -X- _ B-Intervention
, -X- _ I-Intervention
corticosteroids -X- _ I-Intervention
, -X- _ I-Intervention
lopinavir -X- _ I-Intervention
and -X- _ I-Intervention
ritonavir -X- _ I-Intervention
( -X- _ I-Intervention
LPV -X- _ I-Intervention
/ -X- _ I-Intervention
r -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
type -X- _ I-Intervention
I -X- _ I-Intervention
interferon -X- _ I-Intervention
( -X- _ I-Intervention
IFN -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
intravenous -X- _ I-Intervention
immunoglobulin -X- _ I-Intervention
( -X- _ I-Intervention
IVIG -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
SARS -X- _ I-Intervention
convalescent -X- _ I-Intervention
plasma -X- _ I-Intervention
from -X- _ O
both -X- _ O
in -X- _ O
vitro -X- _ O
studies -X- _ O
and -X- _ O
in -X- _ B-Patient
SARS -X- _ I-Patient
patients. -X- _ I-Patient
We -X- _ O
also -X- _ O
searched -X- _ O
for -X- _ O
clinical -X- _ O
trial -X- _ O
evidence -X- _ O
of -X- _ O
treatment -X- _ O
for -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome. -X- _ O
Sources -X- _ O
of -X- _ O
data -X- _ O
were -X- _ O
the -X- _ O
literature -X- _ O
databases -X- _ O
MEDLINE -X- _ O
, -X- _ O
EMBASE -X- _ O
, -X- _ O
BIOSIS -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
Cochrane -X- _ O
Central -X- _ O
Register -X- _ O
of -X- _ O
Controlled -X- _ O
Trials -X- _ O
( -X- _ O
CENTRAL -X- _ O
) -X- _ O
up -X- _ O
to -X- _ O
February -X- _ O
2005. -X- _ O
Data -X- _ O
from -X- _ O
publications -X- _ O
were -X- _ O
extracted -X- _ O
and -X- _ O
evidence -X- _ O
within -X- _ O
studies -X- _ O
was -X- _ O
classified -X- _ O
using -X- _ O
predefined -X- _ O
criteria. -X- _ O
In -X- _ O
total -X- _ O
, -X- _ O
54 -X- _ O
SARS -X- _ O
treatment -X- _ O
studies -X- _ O
, -X- _ O
15 -X- _ O
in -X- _ O
vitro -X- _ O
studies -X- _ O
, -X- _ O
and -X- _ O
three -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
studies -X- _ O
met -X- _ O
our -X- _ O
inclusion -X- _ O
criteria. -X- _ O
Within -X- _ B-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
studies -X- _ I-Outcome
, -X- _ I-Outcome
ribavirin -X- _ I-Outcome
, -X- _ I-Outcome
lopinavir -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
type -X- _ I-Outcome
I -X- _ I-Outcome
IFN -X- _ I-Outcome
showed -X- _ I-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
in -X- _ I-Outcome
tissue -X- _ I-Outcome
culture. -X- _ I-Outcome
In -X- _ O
SARS-infected -X- _ O
patient -X- _ O
reports -X- _ O
on -X- _ O
ribavirin -X- _ O
, -X- _ O
26 -X- _ O
studies -X- _ O
were -X- _ O
classified -X- _ O
as -X- _ O
inconclusive -X- _ O
, -X- _ O
and -X- _ O
four -X- _ O
showed -X- _ O
possible -X- _ O
harm. -X- _ O
Seven -X- _ O
studies -X- _ O
of -X- _ O
convalescent -X- _ O
plasma -X- _ O
or -X- _ O
IVIG -X- _ O
, -X- _ O
three -X- _ O
of -X- _ O
IFN -X- _ O
type -X- _ O
I -X- _ O
, -X- _ O
and -X- _ O
two -X- _ O
of -X- _ O
LPV -X- _ O
/ -X- _ O
r -X- _ O
were -X- _ O
inconclusive. -X- _ O
In -X- _ O
29 -X- _ O
studies -X- _ O
of -X- _ O
steroid -X- _ O
use -X- _ O
, -X- _ O
25 -X- _ O
were -X- _ O
inconclusive -X- _ O
and -X- _ O
four -X- _ O
were -X- _ O
classified -X- _ O
as -X- _ O
causing -X- _ O
possible -X- _ O
harm. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Despite -X- _ O
an -X- _ O
extensive -X- _ O
literature -X- _ O
reporting -X- _ O
on -X- _ O
SARS -X- _ O
treatments -X- _ O
, -X- _ O
it -X- _ O
was -X- _ O
not -X- _ B-Outcome
possible -X- _ I-Outcome
to -X- _ I-Outcome
determine -X- _ I-Outcome
whether -X- _ I-Outcome
treatments -X- _ I-Outcome
benefited -X- _ I-Outcome
patients -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
SARS -X- _ I-Outcome
outbreak. -X- _ I-Outcome
Some -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
harmful. -X- _ I-Outcome
Clinical -X- _ O
trials -X- _ O
should -X- _ O
be -X- _ O
designed -X- _ O
to -X- _ O
validate -X- _ O
a -X- _ O
standard -X- _ O
protocol -X- _ O
for -X- _ O
dosage -X- _ O
and -X- _ O
timing -X- _ O
, -X- _ O
and -X- _ O
to -X- _ O
accrue -X- _ O
data -X- _ O
in -X- _ O
real -X- _ O
time -X- _ O
during -X- _ O
future -X- _ O
outbreaks -X- _ O
to -X- _ O
monitor -X- _ O
specific -X- _ O
adverse -X- _ O
effects -X- _ O
and -X- _ O
help -X- _ O
inform -X- _ O
treatment -X- _ O
. -X- _ O

